Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial

BACKGROUND: Although reperfusion injury has been shown to be responsible for cardiomyocytes death after an acute myocardial infarction, there is currently no drug on the market that reduces this type of injury. TRO40303 is a new cardioprotective compound that was shown to inhibit the opening of the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Le Lamer, Sophie, Paradis, Stéphanie, Rahmouni, Hidayat, Chaimbault, Corinne, Michaud, Magali, Culcasi, Marcel, Afxantidis, Jean, Latreille, Mathilde, Berna, Patrick, Berdeaux, Alain, Pietri, Sylvia, Morin, Didier, Donazzolo, Yves, Abitbol, Jean-Louis, Pruss, Rebacca M, Schaller, Sophie
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3923730/
https://ncbi.nlm.nih.gov/pubmed/24507657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-12-38
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars